BidaskClub cut shares of Myriad Genetics, Inc. (NASDAQ:MYGN) from a strong-buy rating to a buy rating in a report released on Wednesday morning.

A number of other research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Myriad Genetics from a hold rating to a buy rating and set a $28.00 price objective for the company in a report on Monday, July 17th. Piper Jaffray Companies restated a hold rating and issued a $22.00 price objective on shares of Myriad Genetics in a report on Friday, July 14th. Cowen and Company restated a hold rating and issued a $25.00 price objective on shares of Myriad Genetics in a report on Friday, July 14th. J P Morgan Chase & Co restated an underweight rating and issued a $16.00 price objective on shares of Myriad Genetics in a report on Friday, June 30th. Finally, Deutsche Bank AG lifted their price objective on shares of Myriad Genetics from $15.00 to $20.00 and gave the company a sell rating in a report on Monday, May 8th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $22.00.

Myriad Genetics (NASDAQ MYGN) opened at 24.16 on Wednesday. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $32.54. The company has a market capitalization of $1.65 billion, a P/E ratio of 51.62 and a beta of 0.32. The stock’s 50 day moving average is $24.27 and its 200-day moving average is $20.02.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, May 2nd. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.03. The firm had revenue of $196.90 million during the quarter, compared to analysts’ expectations of $188.89 million. Myriad Genetics had a net margin of 4.26% and a return on equity of 10.53%. On average, analysts expect that Myriad Genetics will post $1.01 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades Myriad Genetics, Inc. (NASDAQ:MYGN) to Buy” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/bidaskclub-downgrades-myriad-genetics-inc-nasdaqmygn-to-buy/1456564.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Albert D Mason Inc. boosted its position in shares of Myriad Genetics by 1.5% in the first quarter. Albert D Mason Inc. now owns 16,382 shares of the company’s stock valued at $315,000 after buying an additional 250 shares during the last quarter. Commerzbank Aktiengesellschaft FI boosted its position in shares of Myriad Genetics by 1.7% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 21,733 shares of the company’s stock valued at $417,000 after buying an additional 357 shares during the last quarter. Aperio Group LLC boosted its position in shares of Myriad Genetics by 4.6% in the second quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock valued at $313,000 after buying an additional 534 shares during the last quarter. Creative Planning boosted its position in shares of Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock valued at $122,000 after buying an additional 671 shares during the last quarter. Finally, Foundry Partners LLC boosted its position in shares of Myriad Genetics by 3.6% in the first quarter. Foundry Partners LLC now owns 22,500 shares of the company’s stock valued at $432,000 after buying an additional 775 shares during the last quarter.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.